fulvestrant has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besser, AH; Brafford, P; El-Ashry, D; Gao, W; Gu, M; Hew, KE; Ince, TA; Lu, Y; Miller, PC; Mills, GB; Simpkins, F; Slingerland, JM; Sun, J; Wei, Z; Zhang, G | 1 |
1 other study(ies) available for fulvestrant and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Receptors, Estrogen; Transcriptome; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |